Small Molecules
17 October 2013
Preclinical Results Show Alliqua’s Investigational Lidocaine Transdermal Patch Compares Favorably to Lidoderm Patch17 October 2013
ABRAXANE® Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine17 October 2013
MISODELTM, Ferring’s Removable Misoprostol Vaginal Delivery System, Approved for Labour Induction in European Decentralised Procedure17 October 2013
Gilead’s Single Tablet HIV Regimen Stribild® Demonstrates Durable Viral Suppression Through Three Years of Therapy17 October 2013
ESTEVE Announces Positive Results From its Phase II Clinical Study of E-58425 in Acute Pain17 October 2013
Amarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia17 October 2013
Galapagos presents superior potentiator series for CF16 October 2013
Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma15 October 2013
Kadmon Corporation Announces Development Plans for Selective ROCK 2 Inhibitor, KD025, in Psoriasis, Lupus Nephritis and NASH15 October 2013
Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada15 October 2013
Acacia Pharma Announces Positive Phase II Results With APD515 for Xerostomia in Advanced Cancer15 October 2013
RedHill Biopharma’s RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn’s Study15 October 2013
AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation15 October 2013
Structure of active coagulation factor XIII published – milestone on the way to safe anticoagulation14 October 2013
Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval12 October 2013
Flatley Discovery Lab, LLC Nominates Clinical Candidate for Treatment of Cystic Fibrosis11 October 2013
Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients11 October 2013
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye SyndromeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports